Mocetinostat (MGCD0103)

For research use only. Not for use in humans.

目录号：S1122 别名： MG0103

Mocetinostat (MGCD0103) Chemical Structure

CAS No. 726169-73-9

Mocetinostat (MGCD0103, MG0103) 是一种有效的HDAC抑制剂，对HDAC1抑制作用最强，无细胞试验中IC50为0.15 μM，比作用于HDAC2， 3，和11选择性高2到10倍，对HDAC4， 5， 6， 7，和8没有抑制活性。Mocetinostat (MGCD0103) 可诱导凋亡和自噬。Phase 2。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1563.11	现货
5mg	RMB 1382.65	现货
25mg	RMB 3862.98	现货
50mg	RMB 6314.53	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Mocetinostat (MGCD0103)发表文献86篇：

Cancer Cell, 2021, S1535-6108(20)30662-0

PubMed: 33482121 ( click the link to review the publication )

Cancer Cell, 2016, 29(3):311-323

PubMed: 26977882 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Cancer Discov, 2020, CD-20-0336

PubMed: 32978226 ( click the link to review the publication )

Sci Rep, 2020, 10(1):4337

PubMed: 32152395 ( click the link to review the publication )

Front Genet, 2020, 11:80

PubMed: 32158467 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:752

PubMed: 32850856 ( click the link to review the publication )

Biomed Res Int, 2020, 2020:4705615

PubMed: 32775424 ( click the link to review the publication )

Cancer Sci, 2020, 111(7):2374-2384

PubMed: 32391602 ( click the link to review the publication )

Acta Pharm Sin B, 2020, 10(4):615-627

PubMed: 32322466 ( click the link to review the publication )

J Cancer, 2020, 11(7):1915-1926

PubMed: 32194803 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):33

PubMed: 30728070 ( click the link to review the publication )

Cancer Discov, 2019, 9(4):526-545

PubMed: 30709805 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(1):185-195

PubMed: 30301863 ( click the link to review the publication )

Mol Oncol, 2019, 13(9):1944-1958

PubMed: 31225930 ( click the link to review the publication )

Pharmacol Res, 2019, 146:104281

PubMed: 31125601 ( click the link to review the publication )

ACS Omega, 2019, 4(22):19895-19904

PubMed: 31788622 ( click the link to review the publication )

Commun Biol, 2019, 2:272

PubMed: 31372511 ( click the link to review the publication )

EMBO Rep, 2018, 19(9)

PubMed: 30021835 ( click the link to review the publication )

Cancer Res, 2018, 78(20):5731-5740

PubMed: 30135193 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(2):381-392

PubMed: 28839000 ( click the link to review the publication )

J Virol, 2018, 92(6)

PubMed: 29298886 ( click the link to review the publication )

JCI Insight, 2018, 3(22)125568

PubMed: 30429379 ( click the link to review the publication )
Curr Protoc Pharmacol, 2018, 81(1):e41

PubMed: 29927058 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(11):6334-6349

PubMed: 28369619 ( click the link to review the publication )

Oncogene, 2017, 36(12):1707-1720

PubMed: 27694895 ( click the link to review the publication )

J Mol Cell Cardiol, 2017, 112:74-82

PubMed: 28886967 ( click the link to review the publication )

Biotechnol Bioeng, 2017, 114(11):2660-2667

PubMed: 28667749 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 361(1):140-150

PubMed: 28174211 ( click the link to review the publication )

Pain Physician, 2017, 20(5):E673-E685

PubMed: 28727712 ( click the link to review the publication )

Theriogenology, 2017, 87:298-305

PubMed: 27742403 ( click the link to review the publication )

Circ J, 2017, 82(1):192-202

PubMed: 28747611 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Oncotarget, 2017, 8(4):6319-6329

PubMed: 28030834 ( click the link to review the publication )

Cell Death Discov, 2016, 2:16036

PubMed: 27551526 ( click the link to review the publication )

Mol Oncol, 2016, 10(5):735-750

PubMed: 26775640 ( click the link to review the publication )

ACS Chem Biol, 2016, 11(10):2685-2692

PubMed: 27459069 ( click the link to review the publication )

J Lipid Res, 2016, 57(5):868-81

PubMed: 27013100 ( click the link to review the publication )

Sci Rep, 2016, 6:38407

PubMed: 27910927 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2016, 311(1):L124-34

PubMed: 27233998 ( click the link to review the publication )

J Biol Chem, 2016, 291(16):8745-55

PubMed: 26912657 ( click the link to review the publication )

Mol Cell Biol, 2016, 36(22):2838-2854

PubMed: 27573019 ( click the link to review the publication )

Future Med Chem, 2016, 8(13):1553-71

PubMed: 26971619 ( click the link to review the publication )

Cell Signal, 2016, 28(8):1015-24

PubMed: 27185186 ( click the link to review the publication )

Hypertens Res, 2016, 39(10):709-716

PubMed: 27278287 ( click the link to review the publication )

Nat Commun, 2015, 3;6:10091

PubMed: 26631872 ( click the link to review the publication )

Nucleic Acids Res, 2015, 10.1093/nar/gkv188

PubMed: 25769527 ( click the link to review the publication )
Mol Cancer Ther, 2015, 14(4):1014-23

PubMed: 25673820 ( click the link to review the publication )

Mol Oncol, 2015, 9(7):1447-1457

PubMed: 25957812 ( click the link to review the publication )

FEBS Lett, 2015, 589(10):1080-8

PubMed: 25816750 ( click the link to review the publication )

Sheng Li Xue Bao, 2015, 67(5):447-54

PubMed: 26490061 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25784-800

PubMed: 26329759 ( click the link to review the publication )

Oncotarget, 2015, 6(32):33623-35

PubMed: 26378038 ( click the link to review the publication )

Oncotarget, 2015, 6(24):20449-65

PubMed: 26036259 ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(12):1375-85

PubMed: 26297712 ( click the link to review the publication )

Western University, 2015, Western University

PubMed: ( click the link to review the publication )

Blood, 2014, 123(10):1535-43

PubMed: 24449212 ( click the link to review the publication )

J Heart Lung Transplant, 2014, 33(6):644-53

PubMed: 24746638 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

J Neurosci, 2014, 34(17):6112-22

PubMed: 24760871 ( click the link to review the publication )

BMC Biol, 2014, 12:95

PubMed: 25406762 ( click the link to review the publication )

BMC Biol, 2014, 10.1186/1741-7007-12-30

PubMed: 24779377 ( click the link to review the publication )

Oncogenesis, 2014, 3:e127

PubMed: 25402609 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2014, 274(1):7-17

PubMed: 24200994 ( click the link to review the publication )

Cell Signal, 2014, 26(12):2912-20

PubMed: 25220405 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Fibrogenesis Tissue Repair, 2014, 7:10

PubMed: 25024745 ( click the link to review the publication )

Mol Cell, 2013, 52(3):406-20

PubMed: 24120667 ( click the link to review the publication )

Nat Struct Mol Biol, 2013, 20(3):317-25

PubMed: 23377543 ( click the link to review the publication )

Nat Commun, 2013, 4:2735

PubMed: 24193185 ( click the link to review the publication )

Oncogene, 2013, 33(5):653-64

PubMed: 23524580 ( click the link to review the publication )
J Neurosci, 2013, 33(17):7535-47

PubMed: 23616558 ( click the link to review the publication )

Pain, 2013, 154(9):1668-79

PubMed: 23693161 ( click the link to review the publication )

J Dent Res, 2013, 93(2):148-54

PubMed: 24334408 ( click the link to review the publication )

Mol Pharm, 2013, 10(1):307-18

PubMed: 23186311 ( click the link to review the publication )

J Am Heart Assoc, 2013, 2(5):e000317

PubMed: 24088507 ( click the link to review the publication )

Melanoma Res, 2013, 23(5):341-8

PubMed: 23963286 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

Circ Res, 2012, 110(5):739-48

PubMed: 22282194 ( click the link to review the publication )

Oncogene, 2012, 32(33):3896-903

PubMed: 22945647 ( click the link to review the publication )

Biochem J, 2012, 447(3):457-64

PubMed: 22908849 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52095

PubMed: 23251689 ( click the link to review the publication )

Oncogene, 2011, 30(27):3062-72

PubMed: 21577204 ( click the link to review the publication )

J Biol Chem, 2011, 286(27):23842-51

PubMed: 21489983 ( click the link to review the publication )

PLoS One, 2011, 6(2):e17138

PubMed: 21359182 ( click the link to review the publication )

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述

靶点

HDAC1 ^[1] (Cell-free assay)	HDAC2 ^[1] (Cell-free assay)	HDAC11 ^[1] (Cell-free assay)	HDAC3 ^[1] (Cell-free assay)
0.15 μM	0.29 μM	0.59 μM	1.66 μM

体外研究

MGCD0103按剂量依赖性在纳摩尔浓度或低微摩尔浓度时只能抑制9个人类重组HDACs中的一部分，包括HDAC1, HDAC2, HDAC3, 和HDAC11。在体外，MGCD0103有效抑制人类HDAC1和HDAC2酶，但是不抑制二级HDACs。MGCD0103的外环氨基抑制酶时是必需的，因为作用于HDAC1和HDAC2的HDAC抑制活性已被desamino类似物全部消除。MGCD0103 6 μM时抑制活性达到最高状态，在HCT116细胞中MGCD0103最高抑制全部酶活的75%，而NVP-LAQ824抑制几乎达到100%。MGCD0103抑制A549细胞时也显示出剂量依赖性。^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
PBMC	NHfOTWRCeG:ydH;zbZMhSXO\|YYm=	NX\j[XNkOC53L{KvN{DPxE1?	MVqyOE81QCCq		NXfBbZpzcW6mdXPld{BieG:ydH;zbZMh\G:\|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=>	NIDKbm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MESwOlk1Pyd-MkC0NFY6PDd:L3G+
HeLa	NHLzNVlHfW6ldHnvckBCe3OjeR?=	MljGNVAh\|ryPwrC=	MYm3JIg>	MkXVSG1UVw>?	MUnkbZNzfXC2czDuc5Ju[Wxic4DpcoRt\SClaHXjb5BwcW62IH\1coN1cW:w	NX;nNXJpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC1N\|g5PDBpPkKwOVM5QDRyPD;hQi=>
HeLa	NF7MTJhHfW6ldHnvckBCe3OjeR?=	MXSxNEDPxE4EoB?=	Ml;pOk8yOi9{NDDo	Mn32SG1UVw>?	Mlz0bY5lfWOnczDtbZRwfGmlIHHjZ5VufWyjdHnvckBidmRiZHXsZZlm\CCyMkGg[ZhxemW\|c3nvci=>	M1fnbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNUO4PFQxLz5{MEWzPFg1ODxxYU6=
HeLa	NHTnOJBHfW6ldHnvckBCe3OjeR?=	NHnLWXcxNjNvMUCg{txO	MoTVPEBp	NEfk[3hFVVOR	M1zzeIlv[3KnYYPld{Bk[XOyYYPlJFMh[W6mIEegZYN1cX[jdHnvckBld3OnIHTldIVv\GWwdHz5	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODV\|OEi0NEc,OjB3M{i4OFA9N2F-
HeLa	Ml7MSpVv[3Srb36gRZN{[Xl?	NWHVbW1tOC5\|LUGwJO69VQ>?	MlewPEBp	M1fx[GROW09?	Mn\MbY5kemWjc3XzJIFk\XS7bHH0[YQhUDNiS{mgLGg{UzmDYzmgZZQhOTBizszN	MlzSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB3M{i4OFAoRjJyNUO4PFQxRC:jPh?=
DMS114	NWPuNmNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;uNmlEPTB;NkSwJI5O	Mmn2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4OEK2OFMoRjJyNkiyOlQ{RC:jPh?=
H82	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXfxOJNVUUN3ME2yOVAhdk1?	NUXjTlRPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2PFI3PDNpPkKwOlgzPjR\|PD;hQi=>
H146	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYHJR\|UxRTN3IH7N	NEnOO5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[4NlY1Oyd-MkC2PFI3PDN:L3G+
H526	M17r[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUi2fphzUUN3ME20PFAhdk1?	NFvZNYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[4NlY1Oyd-MkC2PFI3PDN:L3G+
KM-H2	Mn3pSpVv[3Srb36gRZN{[Xl?	M1u3PVHDqM7:TR?=	M1zVVVAvOjVvNEigbC=>	MlH0SG1UVw>?	MXrhZ5RqfmG2ZYOgUmYuc0J?	M2m1clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEiwNVA4Lz5{MEi4NFExPzxxYU6=
L428	NIG4S2hHfW6ldHnvckBCe3OjeR?=	NVjOVo04OcLizszN	NWjZfY9YOC5{NT20PEBp	M2X2ZWROW09?	NH3LbIJi[3SrdnH0[ZMhVkZva1K=	M1naTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEiwNVA4Lz5{MEi4NFExPzxxYU6=
HD-LM2	NHv2cZdHfW6ldHnvckBCe3OjeR?=	NYfWdoVOOcLizszN	MnT6NE4zPS12ODDo	NXXxR2JmTE2VTx?=	M1nQZoFkfGm4YYTld{BPTi2tQh?=	M1[5OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEiwNVA4Lz5{MEi4NFExPzxxYU6=
KM-H2	NH7MfYJHfW6ldHnvckBCe3OjeR?=	MmXNNE42NzFizszN	MnXHNlQwPDhiaB?=	NIfpc4hFVVOR	NF3q[5J2eHKnZ4XsZZRmeyCWTl[t{tEh\G:\|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh6MEGwO{c,OjB6OECxNFc9N2F-
L428	NYe4fFAxTnWwY4Tpc44hSXO\|YYm=	Mn3jNE42NzFizszN	M3;qPVI1NzR6IHi=	NW\MWpd6TE2VTx?=	Mn6xeZBz\We3bHH0[ZMhXE6ILd8xJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh6MEGwO{c,OjB6OECxNFc9N2F-
HD-LM2	NHvnc2ZHfW6ldHnvckBCe3OjeR?=	NF3DXpAxNjVxMTFOwG0>	NFHXZWIzPC92ODDo	MYLEUXNQ	MVX1dJJm\3WuYYTld{BVVkZvzsGg[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?=	M2D4RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEiwNVA4Lz5{MEi4NFExPzxxYU6=
KM-H2	MlTmSpVv[3Srb36gRZN{[Xl?	NGfrSGkyyqEQvF2=	NFntXYwzPC92ODDo	M2TCc2ROW09?	NHruPIFld3ewcnXneYxifGW\|IGjJRXAtKGGldHn2ZZRm\CClYYPwZZNmeyB7IHHu[EA{	NWPsOnZERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4PFAyODdpPkKwPFgxOTB5PD;hQi=>
L428	M1qyNWZ2dmO2aX;uJGF{e2G7	MmHkNeKh\|ryP	NXfn[2JOOjRxNEigbC=>	MonHSG1UVw>?	NHzF[Y9ld3ewcnXneYxifGW\|IGjJRXAtKGGldHn2ZZRm\CClYYPwZZNmeyB7IHHu[EA{	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh6MEGwO{c,OjB6OECxNFc9N2F-
HD-LM2	M2rIW2Z2dmO2aX;uJGF{e2G7	NHjzcI0yyqEQvF2=	M{C2W\|I1NzR6IHi=	M2e1VmROW09?	NXO4UW5{\G:5boLl[5Vt[XSnczDYTWFRNCCjY4TpeoF1\WRiY3HzdIF{\XNiOTDhcoQhOw>?	NUGwWXJNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4PFAyODdpPkKwPFgxOTB5PD;hQi=>
KM-H2	MVTBdI9xfG:\|aYOgRZN{[Xl?	NIqxZnAxNjFxMD61M\|Eh\|ryP	MVG0PEBp	Mly0SG1UVw>?	M{C2bIlv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh6MEGwO{c,OjB6OECxNFc9N2F-
L428	NUXFRmQ3SXCxcITvd4l{KEG\|c3H5	MmTaNE4yNzBwNT:xJO69VQ>?	M4f2ZlQ5KGh?	MYHEUXNQ	NHO5b4dqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5	M4ezclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEiwNVA4Lz5{MEi4NFExPzxxYU6=
HD-LM2	MXvBdI9xfG:\|aYOgRZN{[Xl?	MlrCNE4yNzBwNT:xJO69VQ>?	NEjDWY01QCCq	MXHEUXNQ	MUTpcoR2[2W\|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh6MEGwO{c,OjB6OECxNFc9N2F-
KM-H2	M{jFemZ2dmO2aX;uJGF{e2G7	MmP1NE4yNTJizszN	M2jJe\|I1KGkEoB?=	M3\CcGROW09?	MVzzbI94eyCjY3X0fYxifGmxbjDv[kBpcXO2b37lJFMh[W6mIIXwdoVofWyjdHnvckBw\iC2aHWgZ4VtdCCleXPs[UBz\We3bHH0c5J6KHC{b4TlbY4heDJz	NUjZTY94RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4PFAyODdpPkKwPFgxOTB5PD;hQi=>
L428	M1nyN2Z2dmO2aX;uJGF{e2G7	NWDQZoV7OC5zLUKg{txO	NELIfVQzPCCqwrC=	NITEe3hFVVOR	M{Oxd5Npd3e\|IHHj[ZR6dGG2aX;uJI9nKGirc4TvcoUhOyCjbnSgeZBz\We3bHH0bY9vKG:oIITo[UBk\WyuIHP5Z4xmKHKnZ4XsZZRwenlicILveIVqdiCyMkG=	NUGzSXgxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4PFAyODdpPkKwPFgxOTB5PD;hQi=>
HD-LM2	MVHGeY5kfGmxbjDBd5NigQ>?	M4rEWVAvOS1{IN88US=>	MnPqNlQhcMLi	M{fyfmROW09?	NHHyboZ{cG:5czDhZ4V1gWyjdHnvckBw\iCqaYP0c45mKDNiYX7kJJVxemWpdXzheIlwdiCxZjD0bIUh[2WubDDjfYNt\SC{ZXf1cIF1d3K7IIDyc5RmcW5icEKx	NXi0WZk6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4PFAyODdpPkKwPFgxOTB5PD;hQi=>
KM-H2	MmfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnrTO\|LDqGh?	NX3vOZBXTE2VTx?=	MkLzTWM2OD1{Lki2JO69VQ>?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh6MEGwO{c,OjB6OECxNFc9N2F-
L428	NW\0d\|RKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NV\6UGwxPzMEoHi=	M4nWOmROW09?	MlTHTWM2OD1zLkm2JO69VQ>?	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh6MEGwO{c,OjB6OECxNFc9N2F-
HD-LM2	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFO2ZYE4OsLiaB?=	MojGSG1UVw>?	MWHJR\|UxRTFwOEig{txO	M17RdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEiwNVA4Lz5{MEi4NFExPzxxYU6=
LP1	MUXGeY5kfGmxbjDBd5NigQ>?	NHLRXZgyyqEQvF2=	MXiyOEBp		MorZ[Y5p[W6lZYOgOU1CSy2rbnT1Z4VlKE2DR1WtRVMh\2WwZTDlfJBz\XO\|aX;u	MlL3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzN{G4NlEoRjJzMUexPFIyRC:jPh?=
ANBL6	NFe0c5lHfW6ldHnvckBCe3OjeR?=	NF7TfmwyyqEQvF2=	NFTySXMzPCCq		MoDH[Y5p[W6lZYOgOU1CSy2rbnT1Z4VlKE2DR1WtRVMh\2WwZTDlfJBz\XO\|aX;u	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF5MUiyNUc,OjFzN{G4NlE9N2F-
HMEC	MlrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlzzTWM2OD1zOTFOwG0>	MkmxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF\|MUe0OVUoRjJzM{G3OFU2RC:jPh?=
SW620	Ml2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEH5dFdKSzVyPUGg{txO	NGDHTZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUOxO\|Q2PSd-MkGzNVc1PTV:L3G+
SW48	NFvaRYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fBS2lEPTB;MD64JO69VQ>?	NHLvS\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUOxO\|Q2PSd-MkGzNVc1PTV:L3G+
HT-29	NGrZWolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTBwNzFOwG0>	NHfxdXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUOxO\|Q2PSd-MkGzNVc1PTV:L3G+
HCT15	Mn;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkTRTWM2OD1yLkeg{txO	NHznSY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUOxO\|Q2PSd-MkGzNVc1PTV:L3G+
PAXF 1657L†	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUnVNJlWTUN3ME2wMlMh\|ryP	Mk[xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF\|N{W2O\|koRjJzM{e1Olc6RC:jPh?=
PAXF 546L†	M{fpW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rQdWVEPTB;MT61JO69VQ>?	MoK3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF\|N{W2O\|koRjJzM{e1Olc6RC:jPh?=
Panc-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mkf3SWM2OD1zLkig{txO	M2Dt[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{e1Olc6Lz5{MUO3OVY4QTxxYU6=
MiaPaca-2	MnPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2PqN2VEPTB;MD62JO69VQ>?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5NU[3PUc,OjF\|N{W2O\|k9N2F-
AsPC-1	M4\M[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Moq4SWM2OD1\|Lkmg{txO	NWDFdmlWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO\|U3PzlpPkKxN\|c2Pjd7PD;hQi=>
BxPC-3	NIrrPWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\KSIxGSzVyPUGuNUDPxE1?	MnrqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF\|N{W2O\|koRjJzM{e1Olc6RC:jPh?=
MMCs	MojHSpVv[3Srb36gRZN{[Xl?	NVnwfGtuOcLizszN	M2e1VFYuOjRiaB?=		NV\Od\|c6\G:\|ZT3k[ZBmdmSnboTsfUBqdmirYnn0d{B1cGVidILpcYV1cHmuYYTpc44hdGW4ZXygc4YhUDNvS{mgLGg{NUt7bXWzLS=>	NF65cGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES1NVM4QCd-MkS0OVE{Pzh:L3G+
MMCs	MmHFSpVv[3Srb36gRZN{[Xl?	NWW1WYcxOcLizszN	MVqyOEBp		MWfheYdu\W62czDncI9j[WxiYXPleJlt[XSrb36gcIV3\Wy\|IH;mJIhqe3SxbnWgTFMuUzlxMUSgLGg{NUt7L{G0ZYMqKGGwZDDIOE1MOTJiKFi0MWsyOmGlKR?=	M{WzeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEWxN\|c5Lz5{NES1NVM4QDxxYU6=
MMCs	M4TvZmZ2dmO2aX;uJGF{e2G7	MYSxxsDPxE1?	MYeyOEBp		NI\sdZZqdmO{ZXHz[ZMhUEGWIHHjeIl3cXS7	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR3MUO3PEc,OjR2NUGzO\|g9N2F-
MMCs	MljNSpVv[3Srb36gRZN{[Xl?	NY\ufIhJOC53L{Gg{txO	MoHINlQhcA>?		NWHhfXpUe2ixd4OgOFUu\m:uZDDzeIlufWyjdHnvckBqdiClR13QJIxmfmWucx?=	M373[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEWxN\|c5Lz5{NES1NVM4QDxxYU6=
MMCs	M{C2fmZ2dmO2aX;uJGF{e2G7	MY[xJO69dQ>?	NVjIdYtrOC12ODDo		MVPpcoNz\WG\|ZYOgUnBTSSCycn;0[YlvKGW6cILld5Nqd28EoEKuO-KBmzNwNTDmc4xl	NGDqNm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES1NVM4QCd-MkS0OVE{Pzh:L3G+
Panc1	NE\VS4ZE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MlHmNeKh\|ryP	M3;kV\|czyqCq	NWHqTI5DTE2VTx?=	MYjlcohidmOnczDn[Y1kcXSjYnnu[U1qdmS3Y3XzJINmdGxidnnhZoltcXS7IHTlZ5Jm[XOn	NF\mbYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi3Nlk1OSd-MkW4O\|I6PDF:L3G+
Panc1	NXmzUm52SXCxcITvd4l{KEG\|c3H5	MlqwNeKh\|ryP	MYm3NuKhcA>?	MmC2SG1UVw>?	MkXmd4Vve2m2aYrld{BR[W6lMTDj[YxteyCob4Kg[4Vu[2m2YXLpcoUucW6mdXPl[EBieG:ydH;zbZM>	MmG2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6N{K5OFEoRjJ3OEeyPVQyRC:jPh?=
Panc1	MXzGeY5kfGmxbjDBd5NigQ>?	Mly0NE42NzFxMj61JO69VQ>?	NGf0Wow1QCCq	NGTGVWlFVVOR	NW\NXlRJemWmdXPld{BmgHC{ZYPzbY9vKG:oIGrFRlEhd25iYn;0bEBuWk6DIHHu[EBxem:2ZXnuJIxmfmWuwrC=	MmjWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6N{K5OFEoRjJ3OEeyPVQyRC:jPh?=
Panc1	M{DKNWZ2dmO2aX;uJGF{e2G7	MmLCNE42NzFxMj61JO69VQ>?	NF24S\|U1QCCq	NEn2WpJFVVOR	MYH1dJJm\3WuYYTld{BucVJvMkCz	NGex[249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi3Nlk1OSd-MkW4O\|I6PDF:L3G+
MOLP8	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmG5OFghcA>?		NVLN[5dtUUN3ME2wMlbDuSByLkC0{txO	NXXvOmZyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPVE2OThpPkK2NFkyPTF6PD;hQi=>
T47D	NF:wdotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4rMe\|Q5KGh?		NVOxXpdsUUN3ME2xMlE4KM7:TR?=	NYDQcYlbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zO\|gxOzhpPkK2N\|c5ODN6PD;hQi=>
MCF7	M{C5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUXuWJh6PDhiaB?=		MnyyTWM2OD1yLk[3JO69VQ>?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN5OECzPEc,OjZ\|N{iwN\|g9N2F-
BT549	MlvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MoS0OFghcA>?		MVrJR\|UxRTRwM{ig{txO	NUfwW5JyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zO\|gxOzhpPkK2N\|c5ODN6PD;hQi=>
MDA-MB-231	NIHhRmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkHSOFghcA>?		NY\JfpdyUUN3ME2zMlA1KM7:TR?=	MojLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|N{iwN\|goRjJ4M{e4NFM5RC:jPh?=
HEK293	NHnKPVJHfW6ldHnvckBie3OjeR?=				NYjEOJFQUW6qaXLpeIlwdiCxZjDISGFEOSCrbjDISWszQTNiY3XscJMtKEmFNUC9NE4yO87:TR?=	M1zQN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{C4OVY{Lz5zOEOwPFU3OzxxYU6=
HEK293	MnvGSpVv[3Srb36gZZN{[Xl?				NWXWUIJUUW6qaXLpeIlwdiCxZjDISGFEOyCrbjDISWszQTNiY3XscJMtKEmFNUC9NE43Oc7:TR?=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDNyOEW2N{c,OTh\|MEi1OlM9N2F-
HCT116	M1XaT2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		MWm3NkBpenN?		MmXKRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkK5{txO	NWfYe2FoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1O\|A{PjZpPkG4OVcxOzZ4PD;hQi=>
HCT116	Mk\mSpVv[3Srb36gZZN{[Xl?				NYHrO2RFUW6mdXP0bY9vKG:oIICyNYNqeC:5YX[xJJBzd3SnaX6g[ZhxemW\|c3nvckBqdiCqdX3hckBJS1RzMU[gZ4VtdHNicnXsZZRqfmVidH:gUXMzPzVuIFXDOVA:OC52Nd88US=>	MmP1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3N{CzOlYoRjF6NUewN\|Y3RC:jPh?=
Du145	MY\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M3fkVVczKGi{cx?=		Mmj3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCGdUG0OUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxRTBwNkhOwG0>	MoXTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3N{CzOlYoRjF6NUewN\|Y3RC:jPh?=
A549	M13nXWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M2jNZ\|czKGi{cx?=		NGjvVpVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkpOwG0>	MknGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3N{CzOlYoRjF6NUewN\|Y3RC:jPh?=
HCT116	MkT4R4VtdCCleXPs[UBie3OjeR?=				MYPD[YxtKGO7Y3zlJIFzemW\|dDDpckBpfW2jbjDIR3QyOTZiY3XscJMh[XO\|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEd{L12gdIhie2VuIFXDOVA9Oc7:TR?=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV5MEO2Okc,OTh3N{CzOlY9N2F-
T24	NXPnS3l1TnWwY4Tpc44h[XO\|YYm=				MVTJcoR2[3Srb36gc4YhUDNiaHnzeI9v\SCjY3X0fYxifGmxbjDpckBpfW2jbjDUNlQh[2WubIOgdoVt[XSrdnWgeI8hVVN{N{WsJGVEPTB;MT6zPO69VQ>?	NX3a[IRlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1O\|A{PjZpPkG4OVcxOzZ4PD;hQi=>
HCT116	M4XPU2Fxd3C2b4Ppd{Bie3OjeR?=	MofXNUB2VQ>?			NWrXTHUzUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBJS1RzMU[gZ4VtdHNiYYSgNUB2VQ>?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV5MEO2Okc,OTh3N{CzOlY9N2F-
HCT116	MmjuRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?				MmPYRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvO87:TR?=	NUHoVmgzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxNVQ{ODRpPkG5NVE1OzB2PD;hQi=>
HCT116	NGK2VWpHfW6ldHnvckBie3OjeR?=		MmPCNVYhcHK\|		NGjRVpFKdmS3Y4Tpc44hd2ZicEKxW2FHOS:FSWCxJIV5eHKnc4Ppc44hcW5iaIXtZY4hUEOWMUG2JINmdGy\|IHHzd4V{e2WmIHHzJJR2[nWuaX6gcIV3\WxiYX\0[ZIhOTZiaILzJIJ6KGy3Y3nm[ZJie2ViYYPzZZktKEWFNUC9NE43\|ryP	NUXNU3dzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxNVQ{ODRpPkG5NVE1OzB2PD;hQi=>
T24	MX7GeY5kfGmxbjDhd5NigQ>?		NUnQWWJIOTZiaILz		MXHJcoR2[3Srb36gc4YhcGm\|dH;u[UBJPCCqeYDldoFk\XS7bHH0bY9vKGmwIHj1cYFvKFR{NDDj[YxteyCjZoTldkAyPiCqcoOgZpkhcW2vdX7vZoxwfHSrbnesJGVEPTB:Md88US=>	NWjnfWt3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxNVQ{ODRpPkG5NVE1OzB2PD;hQi=>
HCT116	MUfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?				MXrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckwhUUN3ME2wMlMy\|ryP	NXvIdYNnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG2OVAzOjFpPkKxOlUxOjJzPD;hQi=>
H1299	MnLzRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?				NGKwbmRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFixNlk6KGOnbHzzMEBKSzVyPUGuOFTPxE1?	M1jLcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNkWwNlIyLz5{MU[1NFIzOTxxYU6=
HCT116	NXG5WHhnSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=				NHLX[2xCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{whUUN3ME2wMlMy\|ryP	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd2MkS5Okc,OjF5NEK0PVY9N2F-
Sf9	MUjGeY5kfGmxbjDhd5NigQ>?		NWLmVYN4OiCqcoO=		NHL5cHRKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IFjERWMyKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgbY5kfWKjdHXkJIZweiB{IHjyd{B2e2mwZzDSTGtMNUGlIH\seY9zd2enbnnjJJN2[nO2cnH0[UwhUUN3ME2wMlExOs7:TR?=	NYrTOWZYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwNFkzODNpPkKzNFA6OjB\|PD;hQi=>
HCT116	NWL6ZYFiS3m2b4TvfIlkcXS7IHHzd4F6		Mo\3O\|IhcHK\|		NIP1OmZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjN{N988US=>	M1;LOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkC2PFY4Lz5{M{KwOlg3PzxxYU6=
A549	M2rvcGN6fG:2b4jpZ4l1gSCjc4PhfS=>		M2O4UlczKGi{cx?=		MVfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTB;MT6yO\|nPxE1?	Mn36QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{ME[4OlcoRjJ\|MkC2PFY4RC:jPh?=
MCF7	NH\Ub3lEgXSxdH;4bYNqfHliYYPzZZk>		NWDT[mNFPzJiaILz		NWjXSIx3S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVQvQDB5zszN	M3m3b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkC2PFY4Lz5{M{KwOlg3PzxxYU6=
HCT116	MlTxR5l1d3SxeHnjbZR6KGG\|c3H5		NVPhZVJ3PzJiaILz		M4DsXGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDifUBu\WG\|dYLpcoch[2WubIXsZZIhSVSSIHzleoVtKGGodHXyJFczKGi{czDifUBk\WyuLYTpeIVzKGeubzDhd5NigSxiSVO1NF0xNjgQvF2=	Mk\LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6Mkm0PFMoRjJ\|OEK5OFg{RC:jPh?=
MCF7	NWLvNpZuS3m2b4TvfIlkcXS7IHHzd4F6		NUnZPFdXPzJiaILz		NG\o[WpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIHL5JI1m[XO3cnnu[{Bk\WyudXzhdkBCXFBibHX2[Ywh[W[2ZYKgO\|IhcHK\|IHL5JINmdGxvdHn0[ZIh\2yxIHHzd4F6NCCLQ{WwQVEvOjcQvF2=	MmrWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6Mkm0PFMoRjJ\|OEK5OFg{RC:jPh?=
A549	NHPJe3pEgXSxdH;4bYNqfHliYYPzZZk>		NY\a[5pnPzJiaILz		MmXwR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCkeTDt[YF{fXKrbnegZ4VtdHWuYYKgRXRRKGyndnXsJIFnfGW{IEeyJIhzeyCkeTDj[YxtNXSrdHXyJIdtdyCjc4PhfUwhUUN3ME2xMlc{\|ryP	M{e0PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEK5OFg{Lz5{M{iyPVQ5OzxxYU6=
DU145	MkDjR5l1d3SxeHnjbZR6KGG\|c3H5		M{O5RlczKGi{cx?=		MnvhR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSHUyPDViY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYomgcYVie3W{aX7nJINmdGy3bHHyJGFVWCCuZY\lcEBi\nSncjC3NkBpenNiYomgZ4VtdC22aYTldkBodG9iYYPzZZktKEmFNUC9Nk4xPs7:TR?=	M1TmWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEK5OFg{Lz5{M{iyPVQ5OzxxYU6=
Jurkat	NX\z[2pSSXCxcITvd4l{KGG\|c3H5	NYrsfXROOSC2bzCxNEB2VQ>?	NGTvdW0zPCCqcoO=		NYjrR3JVUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDKeZJs[XRiY3XscJMh[XO\|ZYPz[YQh[XNiUFHSVEBkdGWjdnHn[UBifCBzIITvJFExKHWPIHHmeIVzKDJ2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	Mk\jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6Mkm0PFMoRjJ\|OEK5OFg{RC:jPh?=
HeLa	M{jseWZ2dmO2aX;uJIF{e2G7	Mn;pNUB1dyBzMDD1US=>	NU\1U3dtOjRiaILz		NVjRSlVqUW6qaXLpeIlwdiCxZjDISGFEKGmwIHj1cYFvKEinTHGgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hUDONOVHjJIxmfmWuIHH0JFEhfG9iMUCgeW0h[W[2ZYKgNlQhcHK\|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh{OUS4N{c,OjN6Mkm0PFM9N2F-
Jurkat	MX\GeY5kfGmxbjDhd5NigQ>?	MYWxJJRwKDFyIIXN	NWDxT\|B6OjRiaILz		MYrJcohq[mm2aX;uJI9nKEiGQVOgbY4hcHWvYX6gTpVzc2G2IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJGg{UzmDYzDs[ZZmdCCjdDCxJJRwKDFyIIXNJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	NV3QTo9CRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4Nlk1QDNpPkKzPFI6PDh\|PD;hQi=>
High5	NHPFb\|VHfW6ldHnvckBie3OjeR?=		MUCzJJRwKDJ2IHjydy=>		NHXkfWRKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IFjERWMyKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBqdnOnY4SgbIlocDViY3XscJMhfXOrbnegRYMuVHm\|LWT5dk1NgXNiKHXwd4ltd25vYXPleJltMS2DTVOgZZMhe3Wkc4TyZZRmKGGodHXyJFMhfG9iMkSgbJJ{KGK7IH\seY9z\XOlZX7j[UBie3OjeTygTWM2OD1yLkm1{txO	MomwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOUWwNVgoRjJ2MEm1NFE5RC:jPh?=
HCT116	MnLPRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MmjwO\|IhcHK\|		MXzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxRTFwNUhOwG0>	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB7NUCxPEc,OjRyOUWwNVg9N2F-
A549	NXfIZnRLSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NYTKcVNLPzJiaILz		NVrobmhqSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTB;MT62Oe69VQ>?	NHHVcoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC5OVAyQCd-MkSwPVUxOTh:L3G+
High5	NHnUe25HfW6ldHnvckBie3OjeR?=		NYDjcnVyOyC2bzCyOEBpenN?		NYnweXpnUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDISGFEOyCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhcW6\|ZXP0JIhq\2h3IHPlcIx{KHW\|aX7nJGFkNUy7cz3UfZIuVHm\|IDjldJNqdG:wLXHj[ZR6dClvQV3DJIF{KHO3YoP0doF1\SCjZoTldkA{KHSxIEK0JIhzeyCkeTDmcJVwemW\|Y3XuZ4Uh[XO\|YYmsJGlEPTB;MT62O:69VQ>?	NUXvXmlZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPVUxOThpPkK0NFk2ODF6PD;hQi=>
SNU16	M4PPTGN6fG:2b4jpZ4l1gSCjc4PhfS=>		MlnGO\|IhcHK\|		MmTmR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV25WOTZiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjF2Mt88US=>	NEnQTVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUiwOVQ1Pid-MkW4NFU1PDZ:L3G+
High5	NEnic3ZHfW6ldHnvckBie3OjeR?=		M2fZUFI1KGi{cx?=		Mn30TY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCKRFHDNkBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgbY5{\WO2IFjp[4g2KGOnbHzzJJV{cW6pIFHjMWx6ey2WeYKtUJl{KCincIPpcI9vNWGlZYT5cEkuSU2FIHHzJJN2[nO2cnH0[UBi\nSncjCyOEBpenNiYomg[ox2d3Knc3PlcoNmKGG\|c3H5MEBKSzVyPUCuNVfPxE1?	NHLGXIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUiwOVQ1Pid-MkW4NFU1PDZ:L3G+
High5	NFjnTYhHfW6ldHnvckBie3OjeR?=		MYSzJIhzew>?		NF;1XHJKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIFjERWM{KGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBqdnOnY4SgTIlocDViY3XscJMhfXOrbnegRYMuVHm\|LWT5dk1NgXNiKHXwd4ltd25vYXPleJltMS2DTVOgZZMhe3Wkc4TyZZRmKGGodHXyJFMhcHK\|IHL5JIZtfW:{ZYPj[Y5k\SCjc4PhfUwhUUN3ME2wMlM3\|ryP	MljuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MEW0OFYoRjJ3OEC1OFQ3RC:jPh?=
High5	Mne3SpVv[3Srb36gZZN{[Xl?		NIPiZmIzPCCqcoO=		MULJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKEiGQVOxJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDpcpNm[3RiSHnnbFUh[2WubIOgeZNqdmdiQXOtUJl{NVS7cj3MfZMhMGWyc3nsc44u[WOndInsLU1CVUNiYYOgd5Vje3S{YYTlJIFnfGW{IEK0JIhzeyCkeTDmcJVwemW\|Y3XuZ4Uh[XO\|YYmsJGlEPTB;MD6zPe69VQ>?	NVHq[ZdFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NFU1PDZpPkK1PFA2PDR4PD;hQi=>
HCT116	NFrhc4lEgXSxdH;4bYNqfHliYYPzZZk>		NEW0eZI4OiCqcoO=		M2\4bGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxRTBwM{m2{txO	NWnxdWNFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NFU1PDZpPkK1PFA2PDR4PD;hQi=>
SW620	NFfLe2JEgXSxdH;4bYNqfHliYYPzZZk>		M1nydVczKGi{cx?=		MoHuR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV3c3OjBiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjRzOd88US=>	M2WwT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEC1OFQ3Lz5{NUiwOVQ1PjxxYU6=
MKN45	MnXFR5l1d3SxeHnjbZR6KGG\|c3H5		MnXpO\|IhcHK\|		NEnzblREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOU052NTDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxRTBwNkJOwG0>	MofZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MEW0OFYoRjJ3OEC1OFQ3RC:jPh?=
Hep3B	MoK5R5l1d3SxeHnjbZR6KGG\|c3H5		MYq3NkBpenN?		M{\sRWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeDOEIHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC56MkROwG0>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThyNUS0Okc,OjV6MEW0OFY9N2F-
HepG2	MlrvR5l1d3SxeHnjbZR6KGG\|c3H5		NGfDV3I4OiCqcoO=		NUm4ZW5uS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLki3Ou69VQ>?	Mn7lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MEW0OFYoRjJ3OEC1OFQ3RC:jPh?=
SNU5	M3SzWmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NFr5No44OiCqcoO=		NF[3TFZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUVlV3IHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OS5yMEpOwG0>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThyNUS0Okc,OjV6MEW0OFY9N2F-
A549	MkTER5l1d3SxeHnjbZR6KGG\|c3H5		MnXTO\|IhcHK\|		MUDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9Nk4xQM7:TR?=	M3P5[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEC1OFQ3Lz5{NUiwOVQ1PjxxYU6=
SJSA1	MmrvR5l1d3SxeHnjbZR6KGG\|c3H5		NWL4XZBSPzJiaILz		MnPKR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2pUSTFiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0{NjZ{NN88US=>	MkjiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MEW0OFYoRjJ3OEC1OFQ3RC:jPh?=
MHCC97H	MmG1R5l1d3SxeHnjbZR6KGG\|c3H5		NGDDNZk4OiCqcoO=		NXToVXNxS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUiFQ{m3TEBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyPUSuOVY{\|ryP	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThyNUS0Okc,OjV6MEW0OFY9N2F-
PANC1	Mn\IR5l1d3SxeHnjbZR6KGG\|c3H5		M3fxU\|czKGi{cx?=		MUPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQRW5EOSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVI3Njd5NN88US=>	NX21eVZVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NFU1PDZpPkK1PFA2PDR4PD;hQi=>
U937	NWDPWY1LTnWwY4Tpc44h[XO\|YYm=	MWSxNEB2VQ>?	NWHKXW1jOjRiaILz		MknqTY5pcWKrdHnvckBw\iCKRFHDN{BqdiCqdX3hckBWQTN5IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm\|aX7lMVkh[WOndInsZZRqd25iYYSgNVAhfU1iaX7jeYJifGWmIH\vdkAzPCCqcoOgZpkhX2W\|dHXyckBjdG:2dHnu[{Bu\XSqb3S=	M4X6flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4Mki3N\|ExLz5{NkK4O\|MyODxxYU6=
PC3	NWLicWUzTnWwY4Tpc44h[XO\|YYm=	NGSxUJAyOCC3TR?=	NGO5OVEzPCCqcoO=		M2TxfWlvcGmkaYTpc44hd2ZiSFTBR\|MhcW5iaIXtZY4hWEN\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm\|aX7lMVkh[WOndInsZZRqd25iYYSgNVAhfU1iaX7jeYJifGWmIH\vdkAzPCCqcoOgZpkhX2W\|dHXyckBjdG:2dHnu[{Bu\XSqb3S=	M2rtXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4Mki3N\|ExLz5{NkK4O\|MyODxxYU6=
U937	NYTNTGJOTnWwY4Tpc44h[XO\|YYm=	MVuxNEB2VQ>?	M{nBNVI1KGi{cx?=		M{LLVWlvcGmkaYTpc44hd2ZiSFTBR{BqdiCqdX3hckBWQTN5IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBkgWOuaX6gSUBmgHC{ZYPzbY9vKGmwIHH0JFExKHWPIHnuZ5Vj[XSnZDDmc5IhOjRiaILzJIJ6KFenc4Tldo4h[myxdITpcochdWW2aH;k	NHnTbYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK4O\|MyOCd-Mk[yPFc{OTB:L3G+
Sf9	MmrYSpVv[3Srb36gZZN{[Xl?		M3jzTlExKG2rboO=		NVvOOVV3UW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBnfWyuIHzlcod1cCCqdX3hckBENXSncn3pcoFtKE[OQVeteIFo\2WmIFjERWMyOSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW2Z7IHPlcIx{KHW\|aX7nJGJw[y2OeYOo[ZB{cWyxbj3BZ{kuSU2FIHHzJJN2[nO2cnH0[UBxemW2cnXheIVlKG[xcjCxNEBucW6\|IH\vcIxwf2WmIHL5JJN2[nO2cnH0[UBi\GSrdHnvckBjgSCobIXvdo9u\XS{aXOgcYV1cG:mLDDJR\|UxRTBwNUpOwG0>	NW\WZVNNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1NFE2OTRpPkK4OVAyPTF2PD;hQi=>
TC32	NH;OU5hyUFSVIHHzd4F6				NG\RPWtyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVFOzNkBk\Wyucx?=	M2OySlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY	MV;xTHRUKGG\|c3H5				NWL3S3Y4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFTBU3kh[2WubIO=	NInoV2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	MXPxTHRUKGG\|c3H5				NHnlNnpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=>	NVHsXox[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673	M1O4O5FJXFNiYYPzZZk>				NYHMdlE6eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFG2O\|Mh[2WubIO=	NYjDWWlIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	NFG1dW9yUFSVIHHzd4F6				M{S2OpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
BT-37	MkHOdWhVWyCjc4PhfS=>				M4\0d5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2zO{Bk\Wyucx?=	MnLxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1	MVXxTHRUKGG\|c3H5				M{H3TpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz	M{\YS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
U-2 OS	NGPYe4dyUFSVIHHzd4F6				Mn3FdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFVvMjDPV{Bk\Wyucx?=	NUC5WGdXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2	NF36cppyUFSVIHHzd4F6				NYfHS2M2eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=>	NXvZXZB2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH	MmHldWhVWyCjc4PhfS=>				NWjwPFJYeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJM>	M{jBblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643	MV3xTHRUKGG\|c3H5				NXzib2E3eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=>	NGS1OII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
LAN-5	NEjVZnByUFSVIHHzd4F6				M2\XOJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?=	NX\5[Gp[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12	M{PRV5FJXFNiYYPzZZk>				NITkVldyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStNVIh[2WubIO=	MlLGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh18	M2LFRZFJXFNiYYPzZZk>				M2PQWpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEG4JINmdGy\|	NGHYemI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
OHS-50	NH\tZ3RyUFSVIHHzd4F6				M3TTXJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO=	M2jkWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD	NYq3Npd7eUiWUzDhd5NigQ>?				NXvEdpZweUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLEJINmdGy\|	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
MG 63 (6-TG R)	M3LoR5FJXFNiYYPzZZk>				NGX6bHpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTVegOlMhMDZvVFegVkkh[2WubIO=	NWTCNWxNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
fibroblast cells	M{Gwd5FJXFNiYYPzZZk>				MVTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5Ih[2:wdILvcEBJcCC5aXzkJJR6eGViZnnido9jdGG\|dDDj[Yxtew>?	NIXoZVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh41	NYfU[21veUiWUzDhd5NigQ>?				Ml3DdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN?	MnP1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
A673	NULkUoxpeUiWUzDhd5NigQ>?				NX\TWnVqeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSTZ5MzDj[Yxteyl?	NXPSU\|lMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
DAOY	NU\We3ljeUiWUzDhd5NigQ>?				MWDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDERW9[KGOnbHzz	MlnlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	Ml;EdWhVWyCjc4PhfS=>				MkDKdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2ouT0KPMjDj[Yxtew>?	NYXofndkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
U-2 OS	MlXZdWhVWyCjc4PhfS=>				NYPIfG1reUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXS1{IF;TJINmdGy\|	M4H6UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD	M1\ZUJFJXFNiYYPzZZk>				NG\tcnpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTTCClZXzsdy=>	NWH2S3A2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18	NI\1cXNyUFSVIHHzd4F6				MWTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFE5KGOnbHzz	NI\mfFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh30	Ml20dWhVWyCjc4PhfS=>				NULuZmtZeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWmh\|MDDj[Yxtew>?	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Sf9	M3\jfmZ2dmO2aX;uJIF{e2G7				MkOzTY5pcWKrdHnvckBCe3OjeUqgTGRCSyCrbnjpZol1cW:wIHHzd4F6eyC5ZYLlJJBmem[xcn3l[EBjgSCUZXHjeIlwdiCEaX;sc4d6KEOxcoCuJEhO[Wy4ZYLuMEBR[S5rIIXzbY5oKGm\|b3zheIVlKGi3bXHuMEBz\WOxbXLpcoFvfCCodXzsMYxmdme2aDDISGFEOSCjbnSgMVYh\nKxbTDhJIJi[3Wub4\pdpV{KGW6cILld5Nqd25ic4nzeIVuKGmwIGPmPUBk\WyuczygTWM2OD1yLkGwNu69VQ>?	NYXvS3hjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd{OUiwM{c,S2iHTVLMQE9iRg>?
HCT116	NVSzPVVVSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MVO0PEBpenN?		M3P0b2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVEvOjUQvF2=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|I6QDBxJ{7DbGVOSkx:L3G+
MCF7	NHvj[29CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MVq3NkBpenN?		M2fzWWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3ME2yMlQ6\|ryP	M2nrSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4Ojl6MD:nQmNpTU2ETEyvZV4>
HeLa	MlrPRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NFn3VZQ1QCCqcoO=		Mn6wRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKZVzhJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyPUOuN\|LPxE1?	Mlz0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlczQThyLze+R4hGVUKOPD;hQi=>
HeLa	NIX0WJhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M4THWlczKGi{cx?=		NYTlPXpoSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVMvPDMQvF2=	NWW0fGZsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd{OUiwM{c,S2iHTVLMQE9iRg>?
HCT116	NUe4T4RzSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NHu1VoM4OiCqcoO=		MVfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3ME2zMlUy\|ryP	NH3PXWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzJ7OECvK\|5EcEWPQly8M4E,
HepG2	MoDhRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NXrsUWdsPDhiaILz		MojlRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKZYDHNkBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3ME20MlA2\|ryP	M2Xib\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4Ojl6MD:nQmNpTU2ETEyvZV4>
HepG2	NYr2VopFSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NEXJb5A4OiCqcoO=		NF;4fZlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjldGczKGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVQvOjYQvF2=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|I6QDBxJ{7DbGVOSkx:L3G+
HepG2	NGLyNVRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NEf1dmgzPCCqcoO=		NH[4Vo5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjldGczKGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkAzPCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVUvPzoQvF2=	NGHnXXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzJ7OECvK\|5EcEWPQly8M4E,
A549	MVrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M13XdlczKGi{cx?=		NWjsVGZJSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVEyNjh5zszN	M1fKZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4Ojl6MD:nQmNpTU2ETEyvZV4>
A549	M2fWUmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NYTWXIdjPDhiaILz		NV7x[oRFSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVE1NjV5zszN	NInwcGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzJ7OECvK\|5EcEWPQly8M4E,
HCT116	M{LTNGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MXeyOEBpenN?		MY\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgNlQhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3ME2yPU43Qc7:TR?=	M3HIdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4Ojl6MD:nQmNpTU2ETEyvZV4>
HeLa	MYfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MlviNlQhcHK\|		Mmr3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKZVzhJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBi\nSncjCyOEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyPUSzMljPxE1?	MkD4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlczQThyLze+R4hGVUKOPD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Bad / Bid / Bak / Puma / Bax / Cleaved caspase-9 / Cleaved caspase-3 / Cleaved PARP; PubMed: 27551526 Cell Death Discov (a and b) DU-145 cells were treated with various doses of mocetinostat for 24 h. Western blotting was performed using the indicated antibodies. Ac-H3 / Ac-H4 / Ac-tubulin ; PubMed: 29186204 PLoS One Mocetinostat increased acetylated histone 3 and 4 in a time- and dose-dependent manner in LMS cells. Mocetinostat did not increase acetylated tubulin expression.	27551526 29186204
Immunofluorescence	E-cadherin / ZEB1 ; PubMed: 25872941 EMBO Mol Med Immunoblot and immunofluorescence showing that mocetinostat treatment (1 μM, 48 h) reduced ZEB1 expression and induced E-cadherin in Panc1. Expression of histone deacetylases was not altered by mocetinostat, but histone acetylation was induced. Scale bar 10 μm. Nanog / MHC ; PubMed: 26240433 Stem Cells Transl Med c-Kit+ cells were treated with 2 µM MOCE for 2 or 7 days, as indicated. The cells were double-labeled with anti-Nanog (green) and anti-αMHC (red) antibodies. Nuclei were stained with DAPI (blue). The upper right section of each panel shows the enlargement of the box-selected area. Scale bars = 20 µm.	25872941 26240433
Growth inhibition assay	Cell viability; PubMed: 26378038 Oncotarget B. Cells were treated with increasing concentrations of mocetinostat for 48 hours and assayed by the WST-1 cell viability assay. C. IC50 values were calculated by the GraphPad Prism software.	26378038

体内研究

在裸鼠中，MGCD0103明显抑制人类移植瘤的生长，及抑制肿瘤中组蛋白乙酰化诱导的的相关抗癌活性。MGCD0103每天口服处理携带移植的晚期 A549肿瘤的裸鼠，13天后，明显降低生长，这种作用存在剂量依赖性。MGCD0103与对照组相比，明显阻断肿瘤生长，且体重没有改变。此外, MGCD0103不会使WBC数降低，且耐受性很好。 MGCD0103 作用于许多其他人类移植瘤模型包括NSCLC H1437，是口服有效的。MGCD0103按80 mg/kg 剂量每天口服给药携带H1437肿瘤的动物，13天后，完全抑制肿瘤生长，且动物体重没有下降。 ^[1]MGCD0103降低肺动脉高血压症的效果比tadalafil好，tadalafil是治疗肺动脉高血压症的常规法，是一种血管舒张药。此外, MGCD0103提高肺动脉加速时间，且降低肺动脉的收缩，说明HDAC 抑制剂作用于肺血管具有很好效果。^[2]

激酶实验：^[1]	- 合并体外HDAC酶实验: 根据均相荧光释放法进行脱乙酰化酶活性测定。在实验buffer（包括25 mM HEPES，pH 为8.0, 137 mM NaCl, 1 mM MgCl₂, 2.7 mM KCl）中，纯化的重组HDAC酶和稀释成不同浓度的MGCD0103一起在室温下温育10分钟。加入底物Boc-Lys(ε-Ac)-AMC，在37^oC进一步温育。作用于不同亚型HDAC酶则底物浓度和温育时间都不同。加入胰蛋白酶室温下温育20分钟，脱乙酰化底物释放荧光。在360 , 470, 435 nm 波长处测定荧光信号。
细胞实验：^[1]	- 合并 Cell lines: 人类乳腺上皮细胞(HMEC)和人类包皮成纤维细胞(MRHF) Concentrations: 0-60 μM Incubation Time: 72小时 Method: 人类乳腺上皮细胞(HMEC)和人类包皮成纤维细胞(MRHF)接种在96孔板上，加入不同浓度MGCD0103，在含5% CO₂环境37^oC下温育72小时。加入3-(4,5-二甲基-2-噻唑基)-2,5-二苯基溴化四唑（MTT），最终浓度为0.5 mg/ml，和细胞一起温育4小时，然后加入同体积溶解buffer,buffer包含50% N,N-二甲基甲酰胺,及20% SDS(pH 为4.7)。温育过夜，在630 nm 处标记，在570 nm 处读数，测量溶解的染料。根据相关细胞系的标准生长曲线计算细胞的吸光值。 (Only for Reference)
动物实验：^[1]	- 合并 Animal Models: 携带H1437肿瘤的雌性CD-1裸鼠 Dosages: 80 mg/kg Administration: 口服处理 (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	13 mg/mL (32.79 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 30% PEG400+0.5% Tween80+5% Propylene glycol	30mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Mocetinostat (MGCD0103) SDF

分子量	396.44
化学式	C₂₃H₂₀N₆O
CAS号	726169-73-9
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	MG0103

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04299113	Recruiting	Drug: Vinorelbine\|Drug: Mocetinostat	Rhabdomyosarcoma	Jonsson Comprehensive Cancer Center\|Mirati Therapeutics Inc.\|Phase One Foundation	May 14 2020	Phase 1
NCT02993991	Withdrawn	Drug: Mocetinostat\|Biological: Durvalumab	Squamous Cell Carcinoma Head And Neck\|Squamous Cell Carcinoma Mouth\|Resectable Squamous Cell Carcinoma of Oral Cavity	University Health Network Toronto\|Mirati Therapeutics Inc.\|AstraZeneca	October 10 2017	Phase 1
NCT02236195	Completed	Drug: Mocetinostat	Urothelial Carcinoma	Mirati Therapeutics Inc.	October 2014	Phase 2
NCT00666497	Terminated	Drug: Azacitidine\|Drug: MGCD0103	Acute Myeloid Leukemia (AML)\|Myelodysplastic Syndrome (MDS)	Mirati Therapeutics Inc.	June 2008	Phase 2
NCT00511576	Terminated	Drug: MGCD0103 & Docetaxel	Breast Cancer\|Lung Cancer\|Pulmonary Cancer\|Non-Small-Cell Lung Carcinoma\|Prostate Cancer\|Prostatic Cancer\|Gastric Cancer\|Stomach Cancer	Mirati Therapeutics Inc.	August 2007	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

选择性强的HDAC抑制剂

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
活性最高的HDAC抑制剂

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA批准的HDAC抑制剂

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
最新的HDAC抑制剂

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

研究领域

产品类型

定制您的化合物库

Mocetinostat (MGCD0103)

客户使用Selleck生产的Mocetinostat (MGCD0103)发表文献86篇：

产品安全说明书

HDAC抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Mocetinostat (MGCD0103) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-05-17)

技术支持

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品